









Markets
/
Stocks
/
nasdaq-dna
/

Ginkgo Bioworks Holdings Inc

DNA

10.100USD

+1.780+21.39%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

574.05MMarket Cap

LossP/E TTM



Ginkgo Bioworks Holdings Inc

10.100

+1.780+21.39%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ginkgo Bioworks Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Ginkgo Bioworks Holdings Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 168 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Sell, with the highest price target at 10.00.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ginkgo Bioworks Holdings Inc's Score

Industry at a Glance

Industry Ranking

168 / 392

Overall Ranking

319 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Ginkgo Bioworks Holdings Inc Highlights

StrengthsRisks

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.

Fairly Valued

The company’s latest PE is -1.63, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 31.33M shares, decreasing 0.01% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 189.53K shares of this stock.

Analyst Rating

Based on 4 analysts

Sell

Current Rating

10.000

Target Price

+20.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Ginkgo Bioworks Holdings Inc is 6.72, ranking 224 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 38.84M, representing a year-over-year decrease of 56.39%, while its net profit experienced a year-over-year decrease of 43.18%.

Score

Industry at a Glance

Previous score

6.72

Change



Financials

4.95

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.46

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Ginkgo Bioworks Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Ginkgo Bioworks Holdings Inc is 7.50, ranking 112 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.63, which is -81.81% below the recent high of -0.30 and -164.44% above the recent low of -4.32.

Score

Industry at a Glance

Previous score

7.50

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 168/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Ginkgo Bioworks Holdings Inc is 4.00, ranking 354 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 14.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

4.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Sell

Current Rating

10.000

Target Price

+20.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Ginkgo Bioworks Holdings Inc

DNA

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Ginkgo Bioworks Holdings Inc is 5.32, ranking 320 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 11.56 and the support level at 8.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.75

Change

0.57

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.122

Neutral

RSI(14)

57.770

Neutral

STOCH(KDJ)(9,3,3)

55.953

Buy

ATR(14)

0.840

Low Volatility

CCI(14)

35.609

Neutral

Williams %R

29.674

Buy

TRIX(12,20)

0.006

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

8.928

Buy

MA10

9.191

Buy

MA20

9.442

Buy

MA50

9.101

Buy

MA100

10.544

Sell

MA200

10.324

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Ginkgo Bioworks Holdings Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 82.97%, representing a quarter-over-quarter decrease of 3.61%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 3.58M shares, representing 7.37% of shares outstanding, with 4.49% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Viking Global Investors LP

Star Investors

3.58M

Cascade Investment, L.L.C.

3.32M

-2.22%

BlackRock Institutional Trust Company, N.A.

3.07M

+12.65%

The Vanguard Group, Inc.

Star Investors

2.47M

+4.18%

Baillie Gifford & Co.

Star Investors

3.24M

-1.25%

Erste Asset Management GmbH

2.20M

+10.00%

Anchorage Capital Group, L.L.C.

1.75M

Legal & General Investment Management Ltd.

1.61M

+7.94%

BofA Global Research (US)

1.07M

-11.48%

J.M. Forbes & Co. LLP

1.06M

-1.57%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ginkgo Bioworks Holdings Inc is 3.61, ranking 133 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.56. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Ginkgo Bioworks Holdings Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.